Cardiome/Astellas' Kynapid Approval Seems Likely For Limited Indication, If Additional Trial Holds Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Atrial fibrillation drug has been languishing after "approvable" letter - but approval now seems in the cards for limited indication.
You may also be interested in...
Astellas Likely To Cede U.S. Rights to Vernakalant, Cardiome CEO Says
Cardiome Pharma will likely be announcing a change in ownership for the U.S. rights to the I.V. version of its cardiovascular drug vernakalant by the end of the first quarter, CEO Doug Janzen told analysts on an earnings call
Astellas Likely To Cede U.S. Rights to Vernakalant, Cardiome CEO Says
Analysts speculate that Merck will buy out Astellas' U.S. vernakalant rights in a move that would be positive for Cardiome.
Astellas Likely To Cede U.S. Rights to Vernakalant, Cardiome CEO Says
Analysts speculate that Merck will buy out Astellas' U.S. vernakalant rights in a move that would be positive for Cardiome.